Predicting Health Reform: A Quick Guide To What Will Be In-and What Won't
This article was originally published in RPM Report
The health care reform debate is entering the critical phase. Here are our predictions for where the legislation will end up.
You may also be interested in...
Low rates of patient adherence to medical therapy has been a persistent policy hurdle that has significant commercial implications for drug makers. The health reform debate taking place in Washington should include a solution to the problem-but pharma shouldn't take the lead.
The creation of an independent health council to weigh in on Medicare reimbursement rates may be part of a final health reform bill. The idea has a number of implications for biopharma-good and bad.
There are multiple political strategies playing out in Washington on health care reform that will directly impact the biopharma industry. In the end biopharma will trade margins for volume. The RPM Report makes predictions on what will make it into the final health reform bill.